Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Carillon Eagle Mid Cap Growth Fund Eric Mintz, Christopher Sassouni, David Cavanaugh | “Sarepta Therapeutics develops RNA-targeted medicines and gene therapies for rare neuromuscular diseases. The company reported quarterly revenue that exceeded expectations, but posted a larger than expected loss per share and revised its 2025 sales forecast downward. The stock sold off sharply after a second patient died from acute liver failure after being treated with Elevidys, its gene therapy for patients with Duchenne muscular dystrophy. BSD Analysis: Sarepta is a high-risk, high-reward biotech leveraging gene therapy to treat Duchenne muscular dystrophy, one of the most devastating genetic diseases. The company already has multiple approved therapies, giving it a real revenue base — rare for a gene-therapy name. Launch execution for its latest therapy is crucial, but early data and physician enthusiasm are encouraging. The regulatory path remains complex, yet Sarepta has proven it can navigate FDA scrutiny better than many peers. Manufacturing capacity and pricing will determine the long-term margin profile. If efficacy data continues to strengthen, Sarepta could dominate one of the most meaningful rare-disease markets. The volatility will be brutal, but the upside is equally large.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
